Journal of Clinical Oncology 2016

36 papers
The 2016 edition of the Journal of Clinical Oncology featured 36 papers with a strong emphasis on diagnostic imaging and prostate cancer management. Research frequently explored the utility of multiparametric MRI and fusion-guided biopsies, particularly in biopsy-naive populations and for active surveillance. Prolific contributors during this year included Arvin K. George, Barış Türkbey, Bradford J Wood, and Peter A. Pinto, whose work often focused on refining diagnostic techniques for urologic malignancies. Beyond imaging, the journal addressed public health trends and prognostic modeling. Studies examined enrollment disparities in lung cancer clinical trials between 1990 and 2012 and investigated serum microRNAs as potential early detection markers. Other research analyzed prognostic factors in Hodgkin’s lymphoma and the prevalence of autoimmune comorbidities in patients with metastatic melanoma. Additionally, the year’s publications included efforts to predict post-treatment outcomes, such as erectile function recovery following radiotherapy. This collection reflects a focus on integrating advanced imaging technology with clinical outcomes and epidemiological analysis.

Top Research Directions

The 15 research directions with Journal of Clinical Oncology 2016 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Generalizing Clinical Trial Findings to Real World Populations12.8%
2How Anatomical Location Dictates Tumor Biology and Prognosis12.8%
3Joinpoint Regression for Segmented Trend Analysis12.8%
4Molecular Mechanisms of Sex Differences in Cancer12.8%
5Overcoming the Specificity Gap in Clinical Biomarkers12.8%
6Person-Centered Modeling for Latent Subgroup Identification12.8%
7Predicting Latent Subgroup Membership with Multinomial Regression12.8%
8Predicting Occult Metastasis with Radiomics and Machine Learning12.8%
9Quantifying Gene Expression with Real-Time PCR12.8%
10Real-World Evidence from Population-Based Cancer Registries12.8%
11Resolving Intratumoral Heterogeneity for Precision Cancer Stratification12.8%
12Statistical Power Limits in Rare Variant Genetics12.8%
13Stratified Subgroup Analysis for Identifying Effect Heterogeneity12.8%
14Subtype Specific Genetic Association and Risk Stratification12.8%
15Understanding and Mitigating Self Report Bias12.8%

Download all directions as CSV

Institutions

Institutions credited by Journal of Clinical Oncology 2016 papers: a paper credits every institution named in its affiliations, once. 16 institutions share 3 credited papers.

#InstitutionPapersShare
1Duke University 266.7%
205pecte80 133.3%
3Baylor College of Medicine 133.3%
4Emory University 133.3%
5Fred Hutch Cancer Center 133.3%
6Louisiana State University 133.3%
7Nationwide Children's Hospital 133.3%
8Northwestern University 133.3%
9Roswell Park Comprehensive Cancer Center 133.3%
10St. Jude Children's Research Hospital 133.3%
11SUNY Upstate Medical University 133.3%
12The University of Texas Southwestern Medical Center 133.3%
13University of Illinois Urbana-Champaign 133.3%
14University of Minnesota 133.3%
15University of Pittsburgh Medical Center 133.3%
16Yale University 133.3%

Download all institutions as CSV

About this data

Papers. Journal of Clinical Oncology 2016 lists 36 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 3 of 36 papers (8.3%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-18 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Clinical Oncology 2016”, https://lacuna.tiptreesystems.com/venue/journal-of-clinical-oncology/2016.

Top Authors

AuthorPapers
Bradford J Wood4
Benjamin Haibe-Kains2
Xiaofei Wang2
Andrew S. Lee1
Carlo Lancia1
Jianhua Chen1
John Quackenbush1
Jorge J. Nieva1
Zhen Zhang1

Impactful Papers

Papers from Journal of Clinical Oncology 2016 that shaped research clusters.

Influential

Papers

Title
Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers
Analysis of BRCA1-related functional associations in sporadic triple negative breast cancer: A network-based approach.
A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohort
A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.
A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer.
Behavioral, Social, and Emotional Symptom Comorbidities and Profiles in Adolescent Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
Breast oncology precision medicine: Genomic testing and treatment at the population level.
Causal effects of methotrexate reductions/delays in treatment of high-grade resectable osteosarcoma.
Chemotherapy and radiotherapy in early stage uterine papillary serous and clear-cell carcinoma: A National Cancer Data Base study.
Clinical factors and the role of Wnt regulators in racial disparity of metastatic colorectal cancer survival.
Computerized textural analysis of DCE-MRI to enable identification of HER2-enriched breast cancers.
Detection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance)
Efficacy and safety of rhLTα-Da with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-labelled, controlled, phase IIb trial.
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012
Expanded criteria in men on active surveillance monitored by MRI-TRUS fusion biopsy.
Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III tri
Gene-expression signatures as prognostic for relapse in stage I testicular germ cell tumors (TGCT).
Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose interleukin 2 in metastatic renal cell carcinoma patients (CTEP#7870).
Insomnia symptoms and memory problems in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study.
Missing the mark? Prostate cancer upgrading by systematic biopsy over fusion biopsy.
Multi-institutional evaluation of multiparametric MRI and fusion-guided prostate biopsy in a biopsy-naive population.
Patient-reported levels of concern in the Childhood Cancer Survivor Study (CCSS).
Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
Plasma caveolin-1 to predict disease reclassification in men with early stage prostate cancer in active surveillance.
Practice patterns and outcomes for hormone receptor positive and node negative breast cancer patients with intermediate risk Oncotype DX scores: Analysis of the National Cancer Database.
Predicting return of erectile function following external beam radiotherapy or brachytherapy for prostate cancer using EPIC-CP.
Prevalence of autoimmune comorbidities in patients with metastatic melanoma in the US.
Prognostic factors of advanced Hodgkin’s lymphoma: multivariate analysis of 199 Chinese patients with long-term follow-up.
Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter
Reply to R.L. Bowen et al, M. Froehner et al, J.L. Leow et al, and C. Brady et al
Serum microRNAs/enriched pathways in lung cancer 1-4 years before diagnosis: A pilot study from the HUNT Biobank, Norway.
Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target.
The changing utilization of neoadjuvant chemotherapy among different racial groups and its effect on mastectomy rates.
Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients
Tumor contact length: A novel multiparametric MRI predictor of prostate cancer outcomes.
Validation of a multi-marker panel for early detection of ovarian cancer.